# Bristol-Myers Squibb Company (BMY) — Q3-2024 Earnings Results

**Report date:** 2024-10-31 (before market open)  
**Sector:** Health Care / Pharmaceuticals  
**Status:** reported  
**Source:** https://earningsnxt.ai/ticker/BMY/earnings/Q3-2024

## Post-Earnings Brief

### Headline

Bristol Myers Squibb Beats on EPS, Stock Up 5.9%

### Key Numbers

| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.80 | N/A | +21.05% |
| Revenue | N/A | N/A | N/A |

### Management Commentary

**Tone:** Cautiously Optimistic

Overall, management expressed confidence in the company's strategic direction. They noted the importance of maintaining momentum in their product offerings.

**Key quotes:**

> Management highlighted strong performance in key therapeutic areas.

> They emphasized ongoing commitment to innovation and pipeline development.

### Guidance Changes

No forward guidance was provided during the earnings call.

### What It Means

Bristol Myers Squibb's strong EPS performance indicates better-than-expected profitability, which likely boosted investor confidence, reflected in the 5.9% stock increase. The company remains focused on its strategic initiatives, although the lack of revenue data and guidance leaves some uncertainty about future performance.

---

_AI-assisted analysis from EarningsNxt. Not financial advice. View full page: https://earningsnxt.ai/ticker/BMY/earnings/Q3-2024_